SLAMF7 Recombinant Monoclonal Antibody
-
中文名稱：SLAMF7重組抗體
-
貨號：CSB-RA021369MA1HU
-
規(guī)格：￥1320
-
圖片：
-
IHC image of CSB-RA021369MA1HU diluted at 1:200 and staining in paraffin-embedded human lung cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-Mouse IgG labeled by HRP and visualized using 0.05% DAB. -
Overlay Peak curve showing A549 cells surface stained with CSB-RA021369MA1HU (red line) at 1:200. Then 10% normal goat serum was Incubated to block non-specific protein-protein interactions followed by the antibody (1μg/1*106cells) for 45 min at 4°C. The secondary antibody used was FITC-conjugated Goat Anti-Mouse IgG(H+L) at 1/200 dilution for 35 min at 4°C. Isotype control antibody (green line) was mouse IgG1 (1μg/1*106cells) used under the same conditions. Acquisition of >10,023 events was performed.
-
-
其他：
產(chǎn)品詳情
-
產(chǎn)品描述：CSB-RA021369MA1HU SLAMF7重組單克隆抗體是針對CD319/CRACC靶點研發(fā)的高特異性檢測工具。該抗體識別的SLAMF7蛋白是免疫調(diào)控關(guān)鍵分子，在漿細(xì)胞、NK細(xì)胞及特定T細(xì)胞亞群中參與細(xì)胞活化信號傳導(dǎo)和免疫穩(wěn)態(tài)調(diào)節(jié)。經(jīng)多種平臺驗證，本品在ELISA實驗中顯示優(yōu)異抗原結(jié)合能力，在免疫組化（IHC）應(yīng)用中能清晰定位組織切片中的靶蛋白表達(dá)，推薦工作濃度1:20-1:200；流式檢測（FC）驗證顯示其可精準(zhǔn)標(biāo)記細(xì)胞表面SLAMF7分子，建議使用濃度1:20-1:200。該抗體采用重組技術(shù)制備，具有高批次間重復(fù)性和低交叉反應(yīng)性，適用于免疫細(xì)胞功能研究、腫瘤免疫微環(huán)境分析以及多發(fā)性骨髓瘤等疾病模型中免疫檢查點機制的探索。在實驗設(shè)計中，可用于體外評估免疫治療藥物對效應(yīng)細(xì)胞的作用，或通過組織染色解析疾病相關(guān)的免疫細(xì)胞浸潤特征。本產(chǎn)品嚴(yán)格限于科學(xué)研究領(lǐng)域，為免疫調(diào)控機制和腫瘤免疫治療基礎(chǔ)研究提供可靠檢測方案。
-
Uniprot No.：
-
基因名：
-
別名：SLAMF7 antibody; CS1 antibody; UNQ576/PRO1138 antibody; SLAM family member 7 antibody; CD2 subset 1 antibody; CD2-like receptor-activating cytotoxic cells antibody; CRACC antibody; Membrane protein FOAP-12 antibody; Novel Ly9 antibody; Protein 19A antibody; CD antigen CD319 antibody
-
反應(yīng)種屬：Human
-
免疫原：Recombinant Human SLAMF7 protein
-
免疫原種屬：Homo sapiens (Human)
-
標(biāo)記方式：Non-conjugated
-
克隆類型：Monoclonal
-
抗體亞型：Mouse IgG
-
純化方式：Affinity-chromatography
-
克隆號：7H1
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 -
產(chǎn)品提供形式：Liquid
-
應(yīng)用范圍：ELISA, IHC, FC
-
推薦稀釋比：
Application Recommended Dilution IHC 1:20-1:200 FC 1:20-1:200 -
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情
-
功能：Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K. In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells. May play a role in lymphocyte adhesion. In LPS-activated monocytes negatively regulates production of proinflammatory cytokines.; Isoform 3 does not mediate any NK cell activation.
-
基因功能參考文獻(xiàn)：
- Memory CD8+ T cells from SLE patients displayed decreased amounts of SLAMF7, a surface receptor that characterizes effector CD8+ T cells. Ligation of SLAMF7 increased CD8+ T cell degranulation capacity and the percentage of IFNgamma-producing cells in response to antigen challenge in SLE patients and healthy controls. SLAMF7 engagement promoted cytotoxic lysis of target cells in response to stimulation with viral antig... PMID: 28076903
- phagocytosis of haematopoietic tumour cells during SIRPalpha-CD47 blockade was strictly dependent on SLAM family receptors in vitro and in vivo; in both mouse and human cells, this function required a single SLAM family member, SLAMF7 (also known as CRACC, CS1, CD319), expressed on macrophages and tumour cell targets PMID: 28424516
- Cohort statistics revealed a significant increase of circulating sSLAMF7 in multiple myeloma patients versus normal controls PMID: 27116021
- Blimp-1 regulates the transcription of CS1 gene in NK and B cell lines from multiple myeloma and diffuse large B cell lymphoma patients. PMID: 26310579
- SLAMF7-triggered inhibition is mediated by a mechanism involving Src kinases, CD45, and SHIP-1 that is defective in MM cells PMID: 25312647
- Our data highlight the therapeutic potential of targeting CD319 in rheumatoid arthritis PMID: 24299175
- SLAMF7 plays an inhibitory role in human monocytes to control proinflammatory immune responses. PMID: 23695528
- These results suggest a role for CD319 and CD229 in the systemic lupus erythematosus disease process. PMID: 23956418
- These data suggest an involvement of CRACC-mediated NK cell activation in periodontal tissue destruction and point to a plausible distinction in the pathobiology of aggressive and chronic periodontitis. PMID: 23250953
- CS1-L and CS1-S may differentially regulate human NK cell functions PMID: 15368295
- CS1 may play a role in the regulation of B lymphocyte proliferation during immune responses PMID: 17878365
- CS1 was expressed at adhesion-promoting uropod membranes of polarized Multiple Myeloma cells, andis required for MM cell adhesion to bone marrow stromal cells PMID: 17906076
- HuLuc63 eliminates myeloma cells, at least in part, via NK-mediated ADCC and shows the therapeutic potential of targeting CS1 with HuLuc63 for the treatment of multiple myeloma. PMID: 18451245
顯示更多
收起更多
-
亞細(xì)胞定位：Membrane; Single-pass type I membrane protein.
-
組織特異性：Expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Expression was detected in NK cells, activated B-cells, NK-cell line but not in promyelocytic, B-, or T-cell lines. Expressed
-
數(shù)據(jù)庫鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
-
-
-
-
-
